Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea

Purpose Triple-negative breast cancer (TNBC) accounts for 10–20% of all diagnosed BCs and it is enriched in BRCA1 mutation. Guidelines for Western countries suggest that BRCA 1 / 2 genetic testing should be done for patients with TNBC diagnosed less than 60 years, but there is lack of evidence suppo...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Breast cancer research and treatment Ročník 173; číslo 2; s. 385 - 395
Hlavní autoři:	Ryu, Jai Min, Choi, Hee Jun, Kim, Isaac, Nam, Seok Jin, Kim, Seok Won, Yu, Jonghan, Lee, Se Kyung, Choi, Doo Ho, Park, Yeon Hee, Kim, Jong-Won, Seo, Jeong-sun, Park, Jung-Hoon, Lee, Jeong Eon, Kim, Sung-Won
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	New York Springer US 01.01.2019 Springer Springer Nature B.V
Témata:	Adult Age Factors Analysis Asian Continental Ancestry Group - genetics Asian Continental Ancestry Group - statistics & numerical data BRCA1 protein BRCA1 Protein - genetics BRCA2 protein BRCA2 Protein - genetics Breast cancer Cancer patients Cancer research Care and treatment Clinical Trial Disease-Free Survival DNA DNA Mutational Analysis DNA sequencing Female Follow-Up Studies Gene mutation Genetic aspects Genetic screening Genetic testing Genetic Testing - methods Genetic Testing - statistics & numerical data Health risk assessment High-Throughput Nucleotide Sequencing Humans Kaplan-Meier Estimate Medical centers Medical schools Medicine Medicine & Public Health Middle Aged Mutation Oncology Patient outcomes Population genetics Republic of Korea - epidemiology Retrospective Studies Surgery Survival Triple Negative Breast Neoplasms - diagnosis Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - mortality Republic of Korea Mutation Triple-negative Breast Neoplasms Breast neoplasm / BRCA 1/2
ISSN:	0167-6806, 1573-7217, 1573-7217
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Purpose Triple-negative breast cancer (TNBC) accounts for 10–20% of all diagnosed BCs and it is enriched in BRCA1 mutation. Guidelines for Western countries suggest that BRCA 1 / 2 genetic testing should be done for patients with TNBC diagnosed less than 60 years, but there is lack of evidence supporting genetic testing in Asian populations. We determined the prevalence of germline BRCA 1 / 2 mutations among unselected Korean patients with TNBC and analyzed oncologic outcomes. Methods From among 1628 women with TNBC who underwent surgery at Samsung Medical Center (SMC) between Jul 2008 and Jan 2016, 999 samples were available in the SMC biobank for testing germline BRCA 1 / 2 mutations using next-generation DNA sequencing. Results Overall, 131 Korean patients (13.1%) had BRCA 1 / 2 mutations: 97 (9.7%) were in BRCA 1 , and 35 (3.5%) were in BRCA 2 . One patient had both BRCA 1 and BRCA 2 mutations. Overall, 68 distinct pathologic or likely pathogenic variants (43 BRCA1 and 25 BRCA2 ) were found. Among those diagnosed at ≤ 60 years, the prevalence of BRCA 1 / 2 mutation was 14.5%. The mean age of diagnosis of BRCA1 / 2 mutation carriers was significantly younger than that of non-carriers (45.6 vs. 50.1 years, p < 0.0001). The median follow-up duration was 53.6 months. There were no significant differences in disease-free survival, overall survival, or breast cancer-specific survival ( p = 0.799, 0.092, and 0.124, respectively) between BRCA 1 / 2 carriers and non-carriers, although BRCA 1 / 2 carriers showed significantly worse contralateral breast cancer-free survival ( p < 0.0001) than non-carriers. Conclusion In unselected TNBC patients, we found BRCA 1 / 2 mutations in 13.1% of overall patients and 14.5% of patients ≤ 60 years. We suggest that Korean women with TNBC diagnosed at ≤ 60 years should be tested for BRCA1 / 2 mutation.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	0167-6806 1573-7217 1573-7217
DOI:	10.1007/s10549-018-5015-4